Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA

Abstract : Circulating cell-free DNA (cfDNA) isolated from blood has been identified as a potential biomarker in numerous fields, and has been the object of intensive research over the past decade, although its original discovery dates back 60 years. While it is already used routinely in commercial and clinical practice in oncology and prenatal testing, other potential applications have emerged, including for diabetes, cardiovascular diseases, organ transplantation, autoimmune diseases, sepsis, trauma, and sport management. As with the discovery and development of any biomarker, preanalytical requirements and documentation are as important as analytical requirements. Except for the case of noninvasive prenatal testing and prenatal diagnosis, the implementation of cfDNA in a clinical setting remains limited because of the lack of standardization of cfDNA analysis. In particular, only a few attempts have been made to collect and pool scientific data on the relevant preanalytical factors, and no standard operating procedure has yet been set. For this report, we have performed a thorough and systematic search via MEDLINE® for relevant preanalytical variables and patient factors. These form the basis of the guidelines we propose for analyzing nuclear cfDNA.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Anthony Herrada <>
Soumis le : vendredi 20 décembre 2019 - 13:36:50
Dernière modification le : samedi 21 décembre 2019 - 01:30:38

Lien texte intégral




Romain Meddeb, Ekaterina Pisareva, Alain Thierry. Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clinical Chemistry, American Association for Clinical Chemistry, 2019, 65 (5), pp.623-633. ⟨10.1373/clinchem.2018.298323⟩. ⟨hal-02421322⟩



Consultations de la notice